BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 6.0% from a year ago
Property, plant & equipment (net) stood at $3.16M at the end of Q1 FY2026, down 6.0% from a year earlier and down 4.0% from the prior quarter.
Context
- Property, plant & equipment (net) amounted to 0.8% of total assets at the end of Q1 FY2026, down 1.5 pp from a year earlier.
- Property, plant & equipment (net) increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -6.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Property, Plant & Equipment (Net) vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -6.0% is the 4th highest of 10, against a peer median of -8.4%.
- Property, plant & equipment (net) amounts to 0.8% of total assets for BBOT, versus a peer median of 3.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $103.65M USD | -18.7% | +1.7% | 49.5% | |
| Jun 2026 | $86M USD | -8.4% | -1.0% | 11.9% | |
| Aug 2026 | $68.04M USD | -7.5% | +35.3% | 5.7% | |
| Sep 2026 | $38.41M USD | -12.6% | -9.7% | 3.7% | |
SEPNSepterna, Inc. | Sep 2026 | $23.61M USD | -10.4% | +102.9% | 3.8% |
| Mar 2026 | $13.32M USD | -15.0% | -11.4% | 4.0% | |
| Mar 2026 | $8.56M USD | +59.0% | +34.4% | 3.4% | |
| Mar 2026 | $3.52M USD | +102.3% | +1.6% | 1.2% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $3.16M USD | -6.0% | — | 0.8% |
| Mar 2026 | CHF 2.86M CHF | +80.7% | +38.8% | 1.2% | |
| Peer median (excluding BBOT) | — | -8.4% | +1.7% | 3.8% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.